Title
Relationship Between Anemia and Systemic Inflammation in People Living With HIV and Tuberculosis: A Sub-Analysis of the CADIRIS Clinical Trial
Date Issued
2022
Access level
open access
Resource Type
journal article
Author(s)
Araújo-Pereira M.
Barreto-Duarte B.
Musselwhite L.W.
Vinhaes C.L.
Belaunzaran-Zamudio P.F.
Rupert A.
Montaner L.J.
Lederman M.M.
Sereti I.
Madero J.G.S.
Andrade B.B.
Instituto Gonçalo Moniz
Publisher(s)
Frontiers Media S.A.
Abstract
People with HIV (PWH) are at increased risk of developing active tuberculosis (TB), and anemia is a common complication in both conditions. Anemia in TB patients has been linked to immune activation, levels of inflammatory biomarkers in blood, and risk for HIV disease progression and death. In this study we show that anemia was associated with a more pronounced inflammatory profile in HIV-TB coinfected persons in a cohort of 159 individuals with advanced HIV disease (CD4 count < 100 cells/µL) recruited as part of a randomized clinical trial (NCT00988780). A panel of plasma biomarkers was assessed on plasma obtained prior to combination antiretroviral therapy (cART) initiation. We performed a series of multidimensional analyses including clinical variables and concentrations of inflammatory biomarkers to profile systemic inflammation of PWH with and without anemia. We observed that TB participants presented with moderately lower levels of hemoglobin than non-TB participants. These participants also presented a higher Degree of Inflammatory Perturbation (DIP) score, related to increased levels of IFN-γ and TNF. The DIP was associated with TB coinfection and anemia before cART initiation. Future mechanistic studies are warranted to assess the determinants of such associations and the implications on treatment outcomes.
Volume
13
Language
English
OCDE Knowledge area
Endocrinología, Metabolismo (incluyendo diabetes, hormonas)
Enfermedades infecciosas
Subjects
Scopus EID
2-s2.0-85133844334
PubMed ID
Source
Frontiers in Immunology
ISSN of the container
16643224
Sponsor(s)
The trial was funded as investigator-initiated research by Pfizer Inc, New York, NY, USA. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. The work of I. Sereti was supported by the Intramural Research Program of NIAID/NIH. BA is a senior scientist from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brazil. MA-P and BB-D received a fellowship from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Finance code: 001). MA received a research fellowship from the Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB), Brazil.
JS-M reports grants from BMS, Pfizer, MSD, and Stendhal outside the submitted work. LJM reports grants from Merck and Gene-One.
We thank the study participants, the clinical staff and investigators of the CADIRIS trial team. We also thank Pfizer for the unrestricted research grant provided to the CADIRIS study team to support conduct of the clinical trial from which the clinical specimens were obtained. We also thank Dr. Livio Azzoni for all contributions.
Sources of information:
Directorio de Producción Científica
Scopus